MCID: OPT009
MIFTS: 43

Optic Neuritis malady

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Optic Neuritis

About this section

Aliases & Descriptions for Optic Neuritis:

Name: Optic Neuritis 10 45 47 12 36 65

Classifications:



External Ids:

Disease Ontology10 DOID:1210
ICD1027 H46, H46.9
ICD9CM29 377.3, 377.30
MeSH36 D009902
NCIt42 C84950
UMLS65 C0029134

Summaries for Optic Neuritis

About this section
NIH Rare Diseases:45 Optic neuritis is inflammation of the optic nerve, the nerve that carries the visual signal from the eye to the brain. the condition may cause sudden, reduced vision in the affected eye(s). while the cause of optic neuritis is unknown, it has been associated with autoimmune diseases, infections, multiple sclerosis, drug toxicity and deficiency of vitamin b-12. vision often returns to normal within 2-3 weeks without treatment. in some cases, corticosteroids are given to speed recovery. if known, the underlying cause should be treated. last updated: 1/11/2011

MalaCards based summary: Optic Neuritis is related to retinitis and psoriasis. An important gene associated with Optic Neuritis is AQP4 (Aquaporin 4), and among its related pathways are Cytokines and Inflammatory Response and Spinal Cord Injury. Affiliated tissues include optic nerve which may cause a complete or partial loss of vision, eye and brain, and related mouse phenotype vision/eye.

Disease Ontology:10 An optic nerve disease that results in inflammation located in optic nerve which may cause a complete or partial loss of vision.

Wikipedia:68 Optic neuritis is a demyelinating inflammation of the optic nerve. It is also known as optic papillitis... more...

Related Diseases for Optic Neuritis

About this section

Diseases related to Optic Neuritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 517)
idRelated DiseaseScoreTop Affiliating Genes
1retinitis30.8HLA-A, HLA-B
2psoriasis30.6HLA-A, HLA-B, HLA-DRB1
3listeriosis30.2LTA, TNF
4villonodular synovitis30.1HLA-A, HLA-B
5artery disease29.9HLA-A, HLA-B, HLA-DRB1, TNF
6malaria29.4HLA-A, HLA-B, HLA-DRB1, LTA, TNF
7neuromyelitis optica11.1
8optic papillitis10.8
9leukemia10.5
10endotheliitis10.5
11pancreatitis10.5
12transverse myelitis10.5
13idiopathic juxtafoveal retinal telangiectasia10.5HLA-B, HLA-DRB1
14periventricular leukomalacia10.5HLA-A, HLA-B
15iridocyclitis10.4HLA-A, HLA-B
16hydromyelia10.4HLA-A, HLA-B
17anthracosis10.4HLA-A, HLA-B
18undetermined early-onset epileptic encephalopathy10.4HLA-A, HLA-B
19prostate malignant phyllodes tumor10.4HLA-A, HLA-B
20acquired thrombocytopenia10.4HLA-A, HLA-B
21subcorneal pustular dermatosis10.4HLA-A, HLA-B
22angioid streaks10.4HLA-A, HLA-DRB1
23lacrimal duct obstruction10.4HLA-A, HLA-B
24pediatric t-cell leukemia10.4HLA-DRB1, MOG
25human herpesvirus 810.4HLA-A, HLA-B
26gonococcal iridocyclitis10.4HLA-A, HLA-B
27estrogen excess10.4HLA-A, HLA-B
28neuronitis10.4
29malignant hypertension10.4HLA-A, HLA-B
30colorectal adenoma10.4HLA-DRB1, LTA
31root resorption10.4HLA-A, HLA-B
32treponema infection10.4AQP4, MBP
33acral lentiginous melanoma10.4AQP4, MBP
34cogan syndrome10.4AQP4, MBP
35juvenile pilocytic astrocytoma10.4HLA-A, HLA-B
36congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome10.4HLA-DRB1, TNF
37glycogen storage disease iiia10.3HLA-A, HLA-B
38autoimmune polyglandular syndrome type 210.3HLA-DRB1, TNF
39best1 retinopathy10.3HLA-DRB1, TNF
40pancreatic cancer10.3
41melanoma10.3
42non-distal monosomy 10q10.3HLA-DRB1, TNF
43lactocele10.3HLA-A, HLA-B
44androgen insensitivity syndrome, mild10.3HLA-DRB1, TNF
45lujo hemorrhagic fever10.3HLA-DRB1, TNF
46autoimmune disease of endocrine system10.3MBP, MOG
47postinfectious encephalomyelitis10.3HLA-A, HLA-B, HLA-DRB1
48intermediate uveitis10.3HLA-A, HLA-B, HLA-DRB1
49rhizomelic dysplasia patterson lowry type10.3HLA-DRB1, TNF
50orbit alveolar rhabdomyosarcoma10.3HLA-A, HLA-B

Graphical network of the top 20 diseases related to Optic Neuritis:



Diseases related to optic neuritis

Symptoms for Optic Neuritis

About this section

Drugs & Therapeutics for Optic Neuritis

About this section

Drugs for Optic Neuritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 128)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Mitoxantroneapproved, investigationalPhase 425765271-80-94212
Synonyms:
1,4-Bis(2-(2-hydroxyethylamino)ethyl)amino)-5,8-dihydroxyanthraquinone
1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)-9,10-ANTHRACENEDIONE
1,4-DIHYDROXY-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(2-((2-hydroxyethyl)amino)ethylamino)-9,10-anthracenedione
1,4-Dihydroxy-5,8-bis(5-hydroxy-3-azapentylamino)anthrachinon
1,4-Dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione
1,4-Dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethyl]amino]-9,10-anthracenedione
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthra-9,10-quinone
1,4-dihydroxy-5,8-bis({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione
137635-96-2
2fum
5,8-Bis((2-((2-hydroxyethyl)amino)ethyl)amino)-1,4-dihydroxyanthraquinone
65271-80-9
70476-82-3
70476-82-3 (hydrochloride)
70711-41-0
70711-41-0 (acetate)
70945-62-9
9,10-Anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9CI)
AB00053716
AC1L1HNY
AN-584/42007670
BIDD:PXR0181
BPBio1_000627
BRD-K21680192-300-05-2
BRD-K21680192-300-07-8
BRN 2795126
BSPBio_000569
BSPBio_003160
C11195
C22H28N4O6
CAS-70476-82-3
CCRIS 7604
CHEBI:50729
CHEMBL58
CID4212
D08224
DB01204
DHAD
DHAQ
DHAQ (*Diacetate salt*)
DHAQ HCl
Dihydroxyanthraquinone
DivK1c_000516
HMS2090D05
IDI1_000516
KBio1_000516
KBio2_002135
KBio2_004703
KBio2_007271
KBio3_002660
KBioGR_001531
KBioSS_002135
LS-20638
Liposome Encapsulated Mitoxantrone (LEM)
Lopac-M-6545
Lopac0_000779
MITOXANTRONE, 1,4-DIHYDROXY-5,8-BIS({2-[(2-HYDROXYETHYL)AMINO]ETHYL}AMINO)ANTHRA-9,10-QUINONE
MITOXANTRONE, Mitoxantrone Hydrochloride, Mitoxantrone dihydrochloride, MITOXANTHRONE HYDROCHLORIDE
MIX
MLS002703044
 
Misostol
Misostol (TN)
Mitox
Mitoxanthrone
Mitoxantron
Mitoxantrona
Mitoxantrona [INN-Spanish]
Mitoxantrone
Mitoxantrone (INN)
Mitoxantrone (free base)
Mitoxantrone 2HCl
Mitoxantrone HCl
Mitoxantrone Hydrochloride
Mitoxantrone [INN]
Mitoxantrone dihydrochloride
Mitoxantrone hydrochloride
Mitoxantronum
Mitoxantronum [INN-Latin]
Mitozantrone
Mitozantrone hydrochloride
MolPort-003-849-239
NCGC00015693-01
NCGC00015693-02
NCGC00015693-04
NCGC00162251-01
NCI60_002276
NCI60_002535
NChemBio.2007.10-comp17
NINDS_000516
NSC 279836
NSC-279836
NSC-287836
NSC-299195
NSC-301739
NSC-301739D
NSC279836
NSC299195
NSC301739
Neuro_000153
Novantron
Novantrone
Novantrone(R) (mitoxantrone for injection concentrate)
Prestwick0_000385
Prestwick1_000385
Prestwick2_000385
Prestwick3_000385
S2485_Selleck
SMP2_000179
SMR001549953
SPBio_000756
SPBio_002490
SR-01000076001
SR-01000076001-7
STK631833
Spectrum2_000908
Spectrum3_001590
Spectrum4_000866
Spectrum5_001205
Spectrum_001655
UNII-BZ114NVM5P
VU0244399-2
mitoxantrone
2
PrednisoneapprovedPhase 4, Phase 2, Phase 3126753-03-25865
Synonyms:
(1S,2R,10S,11S,14R,15S)-14-hydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,17-dione
(8S,9S,10R,13S,14S,17R)-17-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,11-dione
(8xi,9xi,14xi)-17,21-dihydroxypregna-1,4-diene-3,11,20-trione
.delta. E
.delta.(sup1)-Cortisone
.delta.-Cortelan
.delta.-Cortisone
.delta.-Cortone
.delta.-E
.delta.1-Cortisone
.delta.1-Dehydrocortisone
.delta.sone
1,2-Dehydrocortisone
1,4-Pregnadiene-17-alpha,21-diol-3,11,20-trione
1,4-Pregnadiene-17.alpha.,21-diol-3,11,20-trione
1,4-Pregnadiene-17alpha,21-diol-3,11,20-trione
1-Cortisone
1-Dehydrocortisone
17,21-Dihydroxypregna-1,4-diene-3,11,20-trione
17alpha,21-Dihydroxy-1,4-pregnadiene-3,11,20-trione
53-03-2
68-59-7
81552_FLUKA
AC-11112
AC1L1LB2
AC1Q29EZ
ACon0_000082
ACon1_000297
AI3-52939
Adasone
Ancortone
Apo-Prednisone
Apo-prednisone
BPBio1_000323
BRD-K85883481-001-04-2
BSPBio_000293
Betapar
Bicortone
Bio-0649
C07370
C21H26O5
CCRIS 2646
CHEBI:8382
CHEMBL635
CID5865
CPD001227202
Cartancyl
Colisone
Cortan
Cortancyl
Cortidelt
Cotone
DB00635
Dacorten
Dacortin
Decortancyl
Decortin
Decortisyl
Dehydrocortisone
Dekortin
Delcortin
Dellacort
Dellacort A
Delta Cortelan
Delta E
Delta E.
Delta-Cortelan
Delta-Dome
Delta-cortelan
Delta-cortisone
Delta-cortone
Delta-dome
Deltacortene
Deltacortisone
Deltacortone
Deltasone
Deltasone, Liquid Pred, Orasone, Adasone, Deltacortisone,Prednisone
Deltison
Deltisona
Deltisone
Deltra
Di-Adreson
Diadreson
EINECS 200-160-3
Econosone
Encorton
Encortone
Enkortolon
Enkorton
Fernisone
Fiasone
HMS1568O15
HMS2090J13
HSDB 3168
Hostacortin
In-Sone
Incocortyl
Juvason
 
Kortancyl
LMST02030180
LS-1325
Liquid Pred
Lisacort
Lodotra
MEGxm0_000443
MLS001061265
MLS001304073
MLS001335907
MLS001335908
MLS002154191
MLS002207083
Me-Korti
Metacortandracin
Meticorten
Meticorten (Veterinary)
Metrevet (Veterinary)
MolPort-001-740-041
NCGC00090766-01
NCGC00090766-02
NCGC00090766-03
NCI-C04897
NCI60_000008
NSC 10023
NSC10023
Nisona
Nizon
Novoprednisone
Nurison
Orasone
Origen Prednisone
P1276
P6254_SIGMA
PRD
Panafcort
Panasol
Paracort
Parmenison
Pehacort
Perrigo Prednisone
Precort
Predeltin
Prednicen-M
Prednicorm
Prednicort
Prednicot
Prednidib
Prednilonga
Prednison
Prednisona
Prednisona [INN-Spanish]
Prednisone
Prednisone Intensol
Prednisone [INN:BAN]
Prednisonum
Prednisonum [INN-Latin]
Prednitone
Prednizon
Prednovister
Presone
Prestwick0_000077
Prestwick1_000077
Prestwick2_000077
Prestwick3_000077
Prestwick_405
Pronison
Pronisone
Rayos
Rectodelt
Retrocortine
S1622_Selleck
SAM002264641
SK-Prednisone
SMR000718760
SMR001227202
SPBio_002214
Servisone
Sone
Sterapred
Supercortil
U 6020
UNII-VB0R961HZT
Ultracorten
Ultracortene
WLN: L E5 B666 CV OV AHTTT&J A1 E1 FV1Q FQ
Winpred
Wojtab
ZINC03875357
Zenadrid
Zenadrid (veterinary)
Zenadrid [veterinary]
delta cortelan
delta(sup 1)-Cortisone
delta(sup 1)-Dehydrocortisone
delta-1-Cortisone
delta-1-Dehydrocortisone
delta-Cortisone
delta-Cortone
3
Interferon beta-1aapproved, investigationalPhase 4, Phase 3194145258-61-36438354
Synonyms:
145258-61-3
Avonex
Avonex (TN)
Avonex Pen
Belerofon
D04554
Extavia
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
Interferon beta-1a
Interferon beta-1a (USAN)
Interferon beta-1a (genetical recombination)
Interferon beta-1a (genetical recombination) (JAN)
Rebif
Rebif Rebidose
4
PrednisoloneapprovedPhase 4, Phase 2, Phase 3, Phase 1108250-24-85755
Synonyms:
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bio-0666
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
CO-Hydeltra
CPD000718761
Co-Hydeltra
Codelcortone
Cordrol
Cortalone
Cotogesic
Cotolone
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
Delta(1)-dehydrohydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Delta-Ef-Cortelan
Delta-Stab
Delta-stab
Deltacortenol
Deltacortril
Deltacortril Enteric
Deltahydrocortisone
Deltasolone
Deltisilone
Depo-Medrol
Derpo PD
Derpo Pd
Dexa-Cortidelt Hostacortin H
Dexa-Cortidelt hostacortin H
Di Adreson F
Di-Adreson F
Di-Adreson-F
Di-adreson F
DiAdresonF
Dicortol
Donisolone
Dydeltrone
EINECS 200-021-7
Eazolin D
Econopred
Econopred Plus
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
Flo-pred
HMS1568H10
HMS2090J05
HSDB 3385
Hostacortin H
Hydeltra
Hydeltra-Tba
Hydeltrasol
Hydeltrone
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
I-Pred
Inflamase Forte
Inflamase Mild
K 1557
Key-Pred
Klismacort
LMST02030179
LS-7669
Lentosone
Lite Pred
M-Predrol
MLS001304083
 
MLS002154250
MLS002207037
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone Acetate
Meti-Derm
Meticortelone
Metreton
Millipred
MolPort-002-507-147
NCGC00179649-01
NSC 9120
NSC9120
NSC9900
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
Ocu-Pred
Ocu-Pred Forte
Omnipred
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
PRDL
PRED-G
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Predni-Dome
Prednicen
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
Prednisolone
Prednisolone (JP15/USP/INN)
Prednisolone (anhydrous)
Prednisolone Acetate
Prednisolone Sodium Phosphate
Prednisolone Tebutate
Prednisolone [INN:BAN:JAN]
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Prestwick_404
Rolisone
S1737_Selleck
SAM002264639
SMR000718761
SPBio_002367
Scherisolon
Solone
Steran
Sterane
Sterolone
Supercortisol
UNII-9PHQ9Y1OLM
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-Hydrogen
Ultracortene-hydrogen
ZINC03833821
component of Ataraxoid
component of K-Predne-Dome
delta(1)-Cortisol
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
prednisolone
5
Glatiramer Acetateapproved, investigationalPhase 4, Phase 3, Phase 294147245-92-93081884
Synonyms:
(2S)-2,6-diaminohexanoic acid
(2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid
(2S)-2-aminopentanedioic acid
(2S)-2-aminopropanoic acid
147245-92-9
AC1MIXQC
Aventis brand of copolymer 1
C089995
CID3081884
COP-1
Copaxone
Copolymer 1
 
Copolymer-1
Copoylmer 1
Glatiramer acetate
Glatiramer acetate [USAN]
L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt)
L-Glutamic acid polymer with L-alanine, L-lysine and L-tyrosine, acetate (salt)
LS-186971
LS-71889
TV 5010
TV-5010
TV5010
Teva brand of copolymer 1
UNII-5M691HL4BO
acetic acid
6
MethylprednisoloneapprovedPhase 4, Phase 2, Phase 3, Phase 1108283-43-26741
Synonyms:
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6alpha-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6-Methylprednisolone
6-alpha-Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
A-methapred
AC1L1N7A
Artisone-Wyeth
Artisone-wyeth
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
Besonia
Bio-0658
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
Depo-Medrol (acetate)
Depo-medrol
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
LMST02030178
LS-118498
Lemod
M0639_SIGMA
M1665
MEPRDL
MLS000028541
MLS001148159
MLS002207191
Medesone
Medixon
Medlone 21
 
Medrate
Medrol
Medrol (TN)
Medrol Adt Pak
Medrol Dosepak
Medrol adt pak
Medrol dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [DCIT]
Metilprednisolone [Dcit]
Metipred
Metrisone
Metrocort
Metysolon
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
NSC-19987
NSC19987
Nirypan
Noretona
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Prestwick_622
Promacortine
Reactenol
S1733_Selleck
SAM002589984
SMR000058330
SPBio_002377
Sieropresol
Solomet
Solu-medrol
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
delta(1)-6alpha-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
methylprednisolone
methylprenisolone
7
Folic Acidapproved, nutraceuticalPhase 4, Phase 1292459-30-36037
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
AI3-26387
AKOS000503224
ARONIS014410
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
Antianemia factor
Apo-Folic
BIDD:ER0563
BIDD:GT0641
BIF0608
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
FOL
Facid
Factor U
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
Folic Acid
Folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
 
Folsaeure
Folsan
Folsaure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
Incafolic
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
LS-2157
Liver Lactobacillus casei factor
MLS001304016
MLS001335861
Millafol
Mission prenatal
Mittafol
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-Amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-Pteroyl-L-glutamic acid
N-[(4-{[(2-Amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-Amino-3,4-dihydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
NINDS_000494
NSC 3073
Nifolin
Nifolin [Denmark]
Novofolacid
Novofolacid [Canada]
PGA
PGA (VAN)
Prestwick3_000627
Prestwick_230
PteGlu
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylglutamate
Pteroylglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
SMP2_000137
SMR000471860
SPBio_001357
SPECTRUM1502020
Serum Folate Level
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
Spectrum_001381
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin B9
Vitamin Bc
Vitamin Be
Vitamin M
bmse000299
folic acid
nchembio.108-comp10
8Peripheral Nervous System AgentsPhase 4, Phase 2, Phase 3, Phase 118510
9Prednisolone hemisuccinatePhase 4, Phase 2, Phase 3, Phase 11082
10Prednisolone acetatePhase 4, Phase 2, Phase 3, Phase 11082
11Prednisolone phosphatePhase 4, Phase 2, Phase 3, Phase 11082
12AnalgesicsPhase 49358
13Adjuvants, ImmunologicPhase 4, Phase 3, Phase 21783
14Immunosuppressive AgentsPhase 4, Phase 3, Phase 2, Phase 110422
15Antirheumatic AgentsPhase 4, Phase 3, Phase 18496
16Topoisomerase InhibitorsPhase 44081
17Protective AgentsPhase 4, Phase 2, Phase 3, Phase 15651
18Neuroprotective AgentsPhase 4, Phase 2, Phase 3, Phase 11376
19interferonsPhase 4, Phase 2, Phase 31930
20Methylprednisolone HemisuccinatePhase 4, Phase 2, Phase 3, Phase 11082
21Interferon-betaPhase 4, Phase 2, Phase 3253
22Immunologic FactorsPhase 4, Phase 3, Phase 2, Phase 118483
23Anti-Infective AgentsPhase 4, Phase 2, Phase 317220
24Antiviral AgentsPhase 4, Phase 2, Phase 38071
25Anti-Inflammatory AgentsPhase 4, Phase 2, Phase 3, Phase 18478
26AntiemeticsPhase 4, Phase 2, Phase 3, Phase 13213
27Antineoplastic Agents, HormonalPhase 4, Phase 2, Phase 3, Phase 14256
28Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Phase 010002
29Methylprednisolone acetatePhase 4, Phase 2, Phase 3, Phase 11082
30Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 4, Phase 2, Phase 3, Phase 1, Phase 09988
31Gastrointestinal AgentsPhase 4, Phase 2, Phase 3, Phase 16401
32glucocorticoidsPhase 4, Phase 2, Phase 3, Phase 13896
33HormonesPhase 4, Phase 2, Phase 3, Phase 1, Phase 011748
34Vitamin B ComplexPhase 4, Phase 12847
35Melanocyte-Stimulating HormonesPhase 4, Phase 098
36Adrenocorticotropic HormonePhase 4, Phase 0133
37beta-endorphinPhase 4, Phase 099
38AntimetabolitesPhase 4, Phase 39454
39Dermatologic AgentsPhase 4, Phase 24555
40FolateNutraceuticalPhase 4, Phase 12924
41Vitamin B9NutraceuticalPhase 4, Phase 12924
42
Epoetin alfaapprovedPhase 3, Phase 2626113427-24-0
Synonyms:
Epogen
 
Erythropoietin precursor
Procrit
43
DalfampridineapprovedPhase 2, Phase 362504-24-51727
Synonyms:
.gamma.-Aminopyridine
275875_ALDRICH
36687_FLUKA
36687_RIEDEL
4 AP
4 Aminopyridine
4 Aminopyridine Sustained Release
4-AP
4-Aminopyridine
4-Aminopyridine 10
4-Aminopyridine Sustained Release
4-Pyridinamine
4-Pyridylamine
4-aminopyridine
5-22-09-00106 (Beilstein Handbook Reference)
504-24-5
A 0152
A0414
A78403_ALDRICH
AB1004971
AC-907/25014071
AC1L1C3R
AC1Q52BM
AI3-52547
AKOS000119896
Amaya
Amino-4 pyridine
Amino-4-Pyridine
Ampydin
Ampyra
Avitrol
Avitrol 200
BB_SC-6974
BRN 0105782
BSPBio_001562
Bio1_000353
Bio1_000842
Bio1_001331
Bio2_000282
Bio2_000762
C13728
C5H6N2
CHEBI:34385
CHEMBL284348
CID1727
Caswell No. 038
Compound 1861
D015761
D04127
Dalfampridine
DivK1c_000572
EINECS 207-987-9
EL-970
EPA Pesticide Chemical Code 069201
EU-0100032
FT-0083754
Fampridina
Fampridine
Fampridine (USAN/INN)
Fampridine SR
Fampridine [USAN:INN]
Fampridine-PR
Fampridine-SR
Fampridinum
Fampyra
HC150041
HMS1361O04
HMS1791O04
HMS1921H15
HMS1989O04
HMS2092F05
HMS501M14
HSDB 6037
IDI1_000572
IDI1_034032
InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7
 
KBio1_000572
KBio2_000282
KBio2_000635
KBio2_002850
KBio2_003203
KBio2_005418
KBio2_005771
KBio3_000563
KBio3_000564
KBio3_001888
KBioGR_000282
KBioGR_001505
KBioSS_000282
KBioSS_000635
LS-130202
Lopac-A-0152
Lopac0_000032
MLS000069400
Mi-W-3
MolPort-000-146-022
N07XX07
NCGC00015009-01
NCGC00015009-03
NCGC00015009-12
NCGC00024890-01
NCGC00024890-02
NCGC00024890-03
NCGC00024890-04
NCGC00024890-05
NCGC00024890-06
NCGC00024890-07
NCGC00024890-08
NCGC00024890-09
NCGC00024890-10
NINDS_000572
NSC 15041
NSC15041
Neurelan
Neurelan (TN)
P-Aminopyridine
PYRIDINE,4-AMINO
Philips 1861
Phillips 1861
Pimadin (free base)
Prc 1237
Pymadin
Pymadine
RCRA waste no. P008
SDCCGMLS-0066228.P001
SMR000058211
SPBio_001486
SPECTRUM1501130
STK298717
Spectrum2_001413
Spectrum3_000914
Spectrum4_001013
Spectrum5_001501
Spectrum_000155
Sustained Release, 4-Aminopyridine
TL8003344
Tocris-0940
UNII-BH3B64OKL9
UPCMLD-DP125
UPCMLD-DP125:001
VMI 10-3
VMI 103
VMI-10-3
VMI-103
VMI103
WLN: T6NJ DZ
[J.Pharmacol.Exp.Ther. 275:864 (1995)]
gamma-Aminopyridine
nchem.892-comp4
p-Aminopyridine
p-Aminopyridine [UN2671] [Poison]
p-Aminopyridine [UN2671] [Poison]
pyridin-4-amine
pyridin-4-ylamine
44
Interferon beta-1bapprovedPhase 2, Phase 382145155-23-3
Synonyms:
Betaseron
Extavia
 
Fibroblast interferon
IFN-beta
Interferon beta precursor
45
SimvastatinapprovedPhase 349379902-63-954454
Synonyms:
(+)-Simvastatin
(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8ar)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one
79902-63-9
AC-1530
AC1L1H1F
AKOS005111006
ARONIS24119
BCBcMAP01_000007
BIDD:GT0769
BPBio1_001001
BRD-K22134346-001-05-8
BRN 4768037
BSPBio_000909
BSPBio_002337
Bio-0672
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,*aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester
Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester
C25H38O5
CCRIS 7558
CHEBI:9150
CHEMBL1064
CID54454
CPD000718785
Cholestat
Coledis
Colemin
Corolin
D00434
D019821
DRG-0320
Denan
DivK1c_006991
Eucor
HMS1570N11
HMS1922H13
HMS2089D12
HMS2093E06
HSDB 7208
InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1
KBio1_001935
KBio2_002197
KBio2_004765
KBio2_007333
KBio3_001557
KBioGR_001244
KBioSS_002197
KS-1113
Kolestevan
L 644128-000U
LS-46264
Labistatin
Lipex
Lipinorm
Liponorm
Lipovas
Lodales
MK 0733
MK 733
MK-0733
MK-733
MK733
MLS001304029
MLS001333077
MLS001333078
 
MLS002154038
Medipo
Modutrol
MolPort-002-507-345
MolPort-002-885-862
NCGC00017324-01
NCGC00017324-02
NCGC00017324-03
Nivelipol
Nor-Vastina
Pantok
Pepstatin
Prestwick0_000865
Prestwick1_000865
Prestwick2_000865
Prestwick3_000865
Prestwick_171
Rechol
Rendapid
S1792_Selleck
S6196_SIGMA
SAM002589969
SMR000718785
SPBio_001881
SPBio_002830
SPECTRUM1504236
STK801938
Simcor
Simovil
Simvast CR
Simvastatin
Simvastatin & Primycin
Simvastatin (JAN/USP/INN)
Simvastatin [USAN:INN:BAN]
Simvastatin [Usan:Ban:Inn]
Simvastatin lactone
Simvastatin, Compactin
Simvastatina
Simvastatina [Spanish]
Simvastatine
Simvastatine [French]
Simvastatinum
Simvastatinum [Latin]
Simvotin
Sinvacor
Sinvascor
Sivastin
SpecPlus_000895
Spectrum2_001671
Spectrum3_000669
Spectrum4_000632
Spectrum5_001428
Spectrum_001717
Statin
Synvinolin
TNP00259
UNII-AGG2FN16EV
Valemia
Vasotenal
Velostatin
Vytorin
ZINC03780893
Zocor
Zocor (TN)
Zocor, Simlup, Simcard, Simvacor, Simvoget, Zorced, Simvastatin
Zocord
[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
butanoic acid, 2,2-dimethyl-,1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)-ethyl]-1-naphthalenyl ester, [1S-[1 alpha,3 alpha,7 beta,8 beta(2S*,4S*),-8a beta
nchembio790-comp16
simvastatin
46Rho(D) Immune GlobulinPhase 3, Phase 2206
47HematinicsPhase 3, Phase 21121
48Immunoglobulins, IntravenousPhase 3, Phase 2211
49Contraceptives, OralPhase 2, Phase 33734
50Potassium Channel BlockersPhase 2, Phase 3151

Interventional clinical trials:

(show top 50)    (show all 78)
idNameStatusNCT IDPhase
1Long Term Study of Avonex Therapy Following a First Attack of Multiple SclerosisCompletedNCT00179478Phase 4
2Effect of High-Dose Prednisolone (Solu Dacortin®) Treatment on Choroidal and Optic Nerve Head Blood Flow in HumansCompletedNCT00312325Phase 4
3Oral Corticotherapy in Megadoses to Treat Multiple Sclerosis During RelapseCompletedNCT00753792Phase 4
4A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease)CompletedNCT00304291Phase 4
5A Phase IV Trial of Neuroprotection With ACTH in Acute Optic NeuritisRecruitingNCT01838174Phase 4
6Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS)RecruitingNCT00910598Phase 4
7Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum DisordersRecruitingNCT02021825Phase 4
8Modeling and Treating the Pathophysiology of Demyelination in Multiple SclerosisTerminatedNCT00854750Phase 4
9Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event.WithdrawnNCT00037115Phase 4
10A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-aWithdrawnNCT00771043Phase 4
11Ampyra for Optic Neuritis in MSCompletedNCT01337986Phase 2, Phase 3
12Optic Neuritis Recovery After Oral or IV CorticosteroidsCompletedNCT01524250Phase 2, Phase 3
13A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)CompletedNCT00856635Phase 3
14Intravenous Immunoglobulin Therapy in Optic NeuritisCompletedNCT00000117Phase 3
15Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled TrialRecruitingNCT01962571Phase 3
16MOdification of VIsual Outcomes After Optic Neuritis in CIS or MS by Gilenya (MOVING Study)RecruitingNCT01647880Phase 2, Phase 3
17A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study)RecruitingNCT01892345Phase 3
18Erythropoietin in Methanol Associated Optic Neuropathy: A Phase-2 Clinical Trial (EPO-MAON Study)RecruitingNCT02376881Phase 3
19Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSDRecruitingNCT02073279Phase 3
20A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum DisordersRecruitingNCT02200770Phase 2, Phase 3
21Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSDRecruitingNCT02028884Phase 3
22Simvastatin Treatment of Patients With Acute Optic NeuritisActive, not recruitingNCT00261326Phase 3
23Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple SclerosisActive, not recruitingNCT02220244Phase 3
24Optic Neuritis Treatment Trial (ONTT)Active, not recruitingNCT00000146Phase 3
25A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse MyelitisActive, not recruitingNCT02398994Phase 3
26Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous MethylprednisoloneActive, not recruitingNCT00004645Phase 3
27An Open Label Extension Trial of Eculizumab in Relapsing NMO PatientsEnrolling by invitationNCT02003144Phase 3
28Using Optical Coherence Tomography (OCT) to Evaluate the Efficacy and Safety of PEGylated Interferon Beta-1a (BIIB017) in Patients With Relapsing Multiple SclerosisWithdrawnNCT01337427Phase 3
29Neuroprotection With Phenytoin in Optic NeuritisCompletedNCT01451593Phase 2
30215ON201 BIIB033 In Acute Optic Neuritis (AON)CompletedNCT01721161Phase 2
31Safety and Efficacy Study of Erythropoietin as add-on Therapy of Methylprednisolone to Treat Acute Optic NeuritisCompletedNCT00355095Phase 2
32Visual Reconstitution Therapy After Optic NeuritisCompletedNCT01274702Phase 2
33Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)CompletedNCT00395200Phase 1, Phase 2
34An Open Label Study of the Effects of Eculizumab in Neuromyelitis OpticaCompletedNCT00904826Phase 1, Phase 2
35Single Oral Doses Study of Nerispirdine on Visual Function in Patients With Multiple SclerosisCompletedNCT00772525Phase 2
36Effect of Vitamin D on Retinal Changes in Patient With Optic Neuritis by Optic Coherence TomographyRecruitingNCT01465893Phase 2
37Amiloride Hydrochlorothiazide as Treatment of Acute Inflammation of the Optic NerveRecruitingNCT01879527Phase 2
38Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis OpticaRecruitingNCT01364246Phase 1, Phase 2
39Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum DisordersRecruitingNCT02249676Phase 2
40Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.RecruitingNCT01845584Phase 2
41Amiloride Clinical Trial In Optic NeuritisActive, not recruitingNCT01802489Phase 2
42AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple SclerosisActive, not recruitingNCT01228396Phase 2
43Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)Active, not recruitingNCT02166346Phase 2
44Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis OpticaActive, not recruitingNCT01339455Phase 1, Phase 2
45Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)Not yet recruitingNCT02521311Phase 2
46Acute Video-oculography for Vertigo in Emergency Rooms for Rapid Triage (AVERT)Not yet recruitingNCT02483429Phase 2
47Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)TerminatedNCT01757691Phase 2
48Neuroprotection and Repair in Optic NeuritisTerminatedNCT01073813Phase 2
49Atacicept in Subjects With Optic NeuritisTerminatedNCT00624468Phase 2
50Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO ExacerbationsCompletedNCT01777412Phase 1

Search NIH Clinical Center for Optic Neuritis


Cochrane evidence based reviews: optic neuritis

Genetic Tests for Optic Neuritis

About this section

Anatomical Context for Optic Neuritis

About this section

MalaCards organs/tissues related to Optic Neuritis:

33
Eye, Brain, Breast, Bone, Lung, Endothelial, T cells

FMA organs/tissues related to Optic Neuritis:

16
Optic nerve which may cause a complete or partial loss of vision

Animal Models for Optic Neuritis or affiliated genes

About this section

MGI Mouse Phenotypes related to Optic Neuritis:

38
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053918.8AQP4, CCR5, LTA, MBP, MOG, TNF

Publications for Optic Neuritis

About this section

Articles related to Optic Neuritis:

(show top 50)    (show all 669)
idTitleAuthorsYear
1
Motor neuron disease: Loss of MHCI exposes motor neurons to astrocyte-mediated toxicity. (26988907)
2016
2
Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response. (23001506)
2014
3
Secondary Kwashiorkor: A Rare Complication of Gastric Bypass Surgery. (25498166)
2014
4
Genome-wide association data provide further support for an association between 5-HTTLPR and major depressive disorder. (22921522)
2013
5
Effect of a 24-week physical training programme (in water and on land) on pain, functional capacity, body composition and quality of life in women with fibromyalgia. (24373364)
2013
6
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case against. (22776974)
2012
7
Review of the final report of the 1998 Working Party on definition, nomenclature and diagnosis of hepatic encephalopathy. (22228879)
2011
8
Activation of caspase-9, but not caspase-2 or caspase-8, is essential for heat-induced apoptosis in Jurkat cells. (20978129)
2010
9
Stable and sensitive flow-through monitoring of phenol using a carbon nanotube based screen printed biosensor. (20498520)
2010
10
Anti-atherosclerotic molecules targeting oxidative stress and inflammation. (19754384)
2009
11
Expression and clinical significance of Ang-2 and MMP-7 in laryngeal carcinoma]. (20359117)
2009
12
Immunotoxicity and environment: immunodysregulation and systemic inflammation in children. (19171930)
2009
13
Founder effect and estimation of the age of the c.892C>T (p.Arg298Cys) mutation in LMNA associated to Charcot-Marie-Tooth subtype CMT2B1 in families from North Western Africa. (18549403)
2008
14
ATP-sensitive potassium channel: a novel target for protection against UV-induced human skin cell damage. (17301957)
2007
15
Systemic diseases in non-inflammatory branch and central retinal artery occlusion--an overview of 416 patients. (18024271)
2007
16
Latanoprost induced iritis after vitrectomy surgery. (25390234)
2007
17
Icodextrin:a major problem for glucose dehydrogenase-based glucose point of care testing systems. (17323845)
2006
18
Establishment of a highly tumorigenic LNCaP cell line having inflammatory cytokine resistance. (16377078)
2006
19
Epidermal growth factor receptor inhibition and non-small cell lung cancer. (16769595)
2006
20
Transcription promoter activity of the human S100A7 gene in oral squamous cell carcinoma cell lines. (16675044)
2006
21
Pancreatic autoantibodies in Italian patients with newly diagnosed type 1 diabetes mellitus over the age of 20 years. (17143785)
2006
22
Novel effect of Y-24180, a presumed specific platelet-activating factor receptor antagonist, on Ca2+ levels and growth of human osteosarcoma cells. (15661567)
2005
23
Hyperphosphorylated tau and amyloid precursor protein deposition is increased in the brains of young drug abusers. (16008828)
2005
24
Transverse myelitis after lumbar steroid injection in a patient with Behcet's disease. (16010282)
2005
25
Urinary endothelin-1 as a marker of renal damage in sickle cell disease. (16144850)
2005
26
Triple incision to treat phimosis in children: an alternative to circumcision. (15008749)
2004
27
Structure-based design of aliskiren, a novel orally effective renin inhibitor. (12927775)
2003
28
Real time fluorescence imaging of PLC gamma translocation and its interaction with the epidermal growth factor receptor. (11331309)
2001
29
New perspectives for the diagnosis and treatment of oligodendroglioma. (12113102)
2001
30
Accelerated silicosis in workers exposed to agate dust in Guangzhou, China. (11439400)
2001
31
Expression of cyclooxygenase-1 and -2 in normal and glaucomatous human eyes. (11581208)
2001
32
Carrier detection and rapid newborn diagnostic test for the common Y393N maple syrup urine disease allele by PCR-RFLP: culturally permissible testing in the Mennonite community. (11486905)
2001
33
Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. (11359874)
2001
34
Hyperstimulation with interleukin 6 inhibits cell cycle progression after hepatectomy in mice. (10960443)
2000
35
An immunohistochemical analysis of cytokine expression in allergic and irritant contact dermatitis. (10954204)
2000
36
AT(1) receptor inhibition does not reduce arterial wall hypertrophy or PDGF-A expression in renal hypertension. (10666094)
2000
37
HLA-G expression in human melanoma cells: protection from NK cytolysis. (10479054)
1999
38
The t(3;12)(q27;q14-q15) with underlying HMGIC-LPP fusion is not determining an adipocytic phenotype. (9598796)
1998
39
Hepatic haematoma related to Glanzmann thrombasthenia in a newborn infant. (8616139)
1996
40
Increased nitric oxide production in patients with hypotension during hemodialysis. (7762912)
1995
41
Chronic suppurative otitis media without cholesteatoma management. (8630764)
1995
42
Significance of amniotic fluid cytokines measurement in threatened preterm labor and premature rupture of the membranes]. (8509668)
1993
43
Soluble interleukin-2 receptor in SAczary syndrome: its origin and clinical application. (8457444)
1993
44
Elective mutism and mental retardation. (8340310)
1993
45
Unusual HLA-B alleles in two tribes of Brazilian Indians. (1317015)
1992
46
Activity of receptors coupled to guanine nucleotide binding regulatory protein in doxorubicin induced cardiomyopathy. (1660348)
1991
47
Molecular cloning of human angiotensinogen cDNA and evidence for the presence of its mRNA in rat heart. (2885106)
1987
48
Role of exogenous factors in alterations of red cell Na+-Li+ exchange and Na+-K+ cotransport in essential hypertension, primary hyperaldosteronism, and hypokalemia. (3012766)
1986
49
Oligosymptomatic Melkersson-Rosenthal syndrome. (520040)
1979
50
Studies of experimental pulmonary embolism and infarction and the development of collateral circulation in the affected lung lobe. (13429204)
1957

Variations for Optic Neuritis

About this section

Expression for genes affiliated with Optic Neuritis

About this section
Search GEO for disease gene expression data for Optic Neuritis.

Pathways for genes affiliated with Optic Neuritis

About this section

GO Terms for genes affiliated with Optic Neuritis

About this section

Cellular components related to Optic Neuritis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1ER to Golgi transport vesicle membraneGO:00125079.5HLA-A, HLA-DRB1

Biological processes related to Optic Neuritis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of chronic inflammatory response to antigenic stimulusGO:000287610.1LTA, TNF
2positive regulation of interferon-gamma productionGO:00327299.7LTA, TNF
3protection from natural killer cell mediated cytotoxicityGO:00422709.7HLA-A, HLA-B
4positive regulation of T cell mediated cytotoxicityGO:00019169.6HLA-A, HLA-B
5defense response to Gram-positive bacteriumGO:00508309.0HLA-A, LTA, TNF
6antigen processing and presentationGO:00198829.0HLA-A, HLA-B, HLA-DRB1

Molecular functions related to Optic Neuritis according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1peptide antigen bindingGO:00426059.3HLA-A, HLA-B

Sources for Optic Neuritis

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet